Acute Renal Failure
Conditions
Keywords
vancomycin, SLEDD-f
Brief summary
1. Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal replacement therapy with high-flux dialyser membrane (helixone). 2. The pore size of helixone is larger than most antibiotics, and vancomycin is supposed to be removed during dialysis. 3. Our study wants to find the amount of vancomycin removed during SLEDD-f, and try to find the most appropriate dose regimen for this kind of patients.
Detailed description
Vancomycin is the most important antibiotic in the treatment of resistant G(+) bacteria infections. Close monitor of serum level is important to ensure its safety and effectiveness. So far there is not enough data to support the optimal dose regimen of vancomycin in patients on SLEDD-f. In this study, we draw blood levels between 2 doses of vancomycin to determine the pharmacokinetic parameters of vancomycin and fraction removed by SLEDD-f so as to determine the most appropriate dose regimen.
Interventions
DEVICEsustained low efficiency daily hemodiafiltration (SLEDD-f)
vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
Sponsors
National Taiwan University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute renal failure of any cause * Use SLEDD-f as renal replacement therapy * Priscribe vancomycin for a known or suspected infection
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of vancomycin removed during one course of SLEDD-f | 8 hr (during one course of SLEDD-f) |
| The pharmacokinetics and dosing regimen of vancomycin in patients on SLEDD-f. | 26 hr |
Countries
Taiwan
Outcome results
None listed